| Product Code: ETC9616497 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Taiwan Clinical Oncology NGS Market Overview |
3.1 Taiwan Country Macro Economic Indicators |
3.2 Taiwan Clinical Oncology NGS Market Revenues & Volume, 2021 & 2031F |
3.3 Taiwan Clinical Oncology NGS Market - Industry Life Cycle |
3.4 Taiwan Clinical Oncology NGS Market - Porter's Five Forces |
3.5 Taiwan Clinical Oncology NGS Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 Taiwan Clinical Oncology NGS Market Revenues & Volume Share, By Workflow, 2021 & 2031F |
3.7 Taiwan Clinical Oncology NGS Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Taiwan Clinical Oncology NGS Market Revenues & Volume Share, By End-use, 2021 & 2031F |
4 Taiwan Clinical Oncology NGS Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Taiwan |
4.2.2 Growing adoption of precision medicine in oncology |
4.2.3 Technological advancements in next-generation sequencing (NGS) technologies |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for clinical oncology NGS in Taiwan |
4.3.2 High costs associated with NGS testing |
4.3.3 Limited awareness and accessibility of clinical oncology NGS services in certain regions of Taiwan |
5 Taiwan Clinical Oncology NGS Market Trends |
6 Taiwan Clinical Oncology NGS Market, By Types |
6.1 Taiwan Clinical Oncology NGS Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Technology, 2021- 2031F |
6.1.3 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.1.4 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F |
6.1.5 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Targeted Sequencing & Resequencing Centrifuges, 2021- 2031F |
6.2 Taiwan Clinical Oncology NGS Market, By Workflow |
6.2.1 Overview and Analysis |
6.2.2 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Pre-Sequencing, 2021- 2031F |
6.2.3 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Sequencing, 2021- 2031F |
6.2.4 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Data Analysis, 2021- 2031F |
6.3 Taiwan Clinical Oncology NGS Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Screening, 2021- 2031F |
6.3.3 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Companion Diagnostics, 2021- 2031F |
6.3.4 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Other Diagnostics, 2021- 2031F |
6.4 Taiwan Clinical Oncology NGS Market, By End-use |
6.4.1 Overview and Analysis |
6.4.2 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Taiwan Clinical Oncology NGS Market Revenues & Volume, By Laboratories, 2021- 2031F |
7 Taiwan Clinical Oncology NGS Market Import-Export Trade Statistics |
7.1 Taiwan Clinical Oncology NGS Market Export to Major Countries |
7.2 Taiwan Clinical Oncology NGS Market Imports from Major Countries |
8 Taiwan Clinical Oncology NGS Market Key Performance Indicators |
8.1 Average turnaround time for clinical oncology NGS testing |
8.2 Number of oncology clinics/hospitals offering NGS services |
8.3 Adoption rate of NGS-based treatment decisions by oncologists |
9 Taiwan Clinical Oncology NGS Market - Opportunity Assessment |
9.1 Taiwan Clinical Oncology NGS Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 Taiwan Clinical Oncology NGS Market Opportunity Assessment, By Workflow, 2021 & 2031F |
9.3 Taiwan Clinical Oncology NGS Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Taiwan Clinical Oncology NGS Market Opportunity Assessment, By End-use, 2021 & 2031F |
10 Taiwan Clinical Oncology NGS Market - Competitive Landscape |
10.1 Taiwan Clinical Oncology NGS Market Revenue Share, By Companies, 2024 |
10.2 Taiwan Clinical Oncology NGS Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here